SI
IOVA icon

Sofinnova Investments’s Iovance Biotherapeutics IOVA Stock Holding History

Sofinnova Investments’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-30,958
Closed -$523K – 64
2018
Q1 		$523K Buy
+30,958
New +$469K 0.09% 28

Other funds holding IOVA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Sofinnova Investments's IOVA Position: Q2 2018 in Review

Sofinnova Investments sold out of Iovance Biotherapeutics (IOVA) in Q2 2018, closing a stake of 30,958 shares — an estimated $523K sold.

Sofinnova Investments first reported a position in IOVA in Q1 2018 and held it in 1 quarter. The position peaked at $523K in Q1 2018. 126 funds tracked by Wall St. Rank hold IOVA as of Q2 2018.

  • Sofinnova Investments reported no remaining Iovance Biotherapeutics position as of Q2 2018 after selling out during the quarter.
  • Sofinnova Investments sold 30,958 Iovance Biotherapeutics shares in Q2 2018, an estimated $523K.
  • Sofinnova Investments first reported a position in Iovance Biotherapeutics in Q1 2018 and held it in 1 quarter.
  • Sofinnova Investments's Iovance Biotherapeutics position peaked at $523K in Q1 2018.
  • 126 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2018.

Based on Sofinnova Investments's 13F filing for Q2 2018, filed 14 Aug 2018.